Heavy Metals and Hashimoto's: The Thyroid Connection
The thyroid runs on selenoenzymes, and mercury is one of the strongest selenium antagonists there is. What is plausible about that, what is established, and what remains hypothesis.
What this article is about, and what it is not
This article zooms in on a single sub-topic within the heavy-metal field: the thyroid and Hashimoto's. The general heavy-metal mechanics, the diagnostics and the sources are covered in the heavy-metals overview page. Here we look only at what might make the thyroid so particularly susceptible, and at the honest question of when the suspicion is even worth pursuing.
When the numbers look right and you still feel awful
Many people with Hashimoto's know this trajectory. The diagnosis is made, the levothyroxine is dialled in, the TSH sits in the target range. And yet something lingers: an exhaustion that will not lift, brain fog, weight problems, the diffuse sense that your body keeps working against you.
When you ask why, the answer is usually the same: the cause of Hashimoto's is simply unknown, a mix of genetic predisposition and nonspecific triggers. That is not wrong. But it is not the end of the story either.
This article follows a lead that almost never comes up in that conversation: whether and how a heavy metal, mercury above all, could play a role. What is mechanistically plausible about it, what is established, what remains hypothesis, and when the question is even clinically worth asking. Without fear marketing, and without promising you that a test will dissolve your Hashimoto's.
"Cause unknown" does not mean "there is nothing to check." Heavy metals are not a proven cause of Hashimoto's, and anyone who claims so goes beyond the data. But they are an unusually concrete mechanistic lead. The difference between "proven cause" and "plausible, testable lead" is decisive. I try to keep it consistently apart throughout this text.
Why the thyroid in particular could be a plausible target
The thyroid is one of the most selenium-rich organs in your body. That is no accident, but a necessity. Three of its central tools are so-called selenoenzymes: enzymes that simply cannot work without the trace element selenium. This is exactly where things get interesting.
Mercury binds selenium with very high affinity. Within the body, it preferentially seeks out the very places where selenium sits. And when the most important thyroid enzymes happen to carry selenium at their core, that creates a biologically understandable line of conflict. This is the heart of this page.
The two switch points at stake
1. The deiodinases (DIO1, DIO2, DIO3). These enzymes convert the storage hormone T4 into the actually active T3. T4 alone does little for your cells; only T3 switches your metabolism on. The deiodinases carry selenium in their catalytic centre.
2. The glutathione peroxidases (GPx). To make its hormones, the thyroid produces hydrogen peroxide itself, a cell toxin. The GPx, also selenoenzymes, neutralise it again and protect the thyrocyte from its own tool.
Both enzyme families need selenium. Both sit exactly where mercury likes to dock. From this follows the central hypothesis of this text.
The scientific basis for this is well established. Two large mechanistic reviews describe just how dependent the thyroid is on its selenoenzymes.
Köhrle and Gärtner summarised what makes the thyroid a selenium hotspot: the three deiodinases as well as the glutathione peroxidases and thioredoxin reductases are all selenoproteins that govern hormone activation and oxidative protection. The thyroid is among the most selenium-rich tissues of all. For you this means: the key enzymes of your thyroid need selenium, and this is exactly where a possible mercury conflict comes in.
Köhrle & Gärtner, Best Pract Res Clin Endocrinol Metab. 2009. DOI: 10.1016/j.beem.2009.08.002Schweizer and colleagues described the thyrocyte's dilemma in more detail: to synthesise hormones, the cell continuously produces hydrogen peroxide and relies on glutathione peroxidases and thioredoxin reductases to protect itself from it. Selenium acts protectively here both directly and indirectly. For you this means: the thyroid works permanently with a cell toxin that it can only neutralise with selenium enzymes, a system that reacts sensitively to anything that blocks selenium.
Schweizer, Chiu & Köhrle, Antioxid Redox Signal. 2008. DOI: 10.1089/ars.2008.2054How mercury could intervene concretely
The mechanistic reviews show why the thyroid needs selenium. Other work shows what happens when mercury gets in the way. Here the data are strikingly direct at the molecular level, even though they come mostly from cell culture and animal models.
Mercury seeks out the selenium
Methylmercury can bind directly to the selenol group of a glutathione peroxidase and inhibit its activity. In a human kidney cell line it was shown that adding selenium softens this effect. This is a molecular hint at the mercury–selenium antagonism. What was studied there is a related isoform in kidney cells, not the thyroid itself.
Hormone conversion can slow down
In an animal model, the mercury compound thimerosal lowered deiodinase activity in several tissues without changing the amount of enzyme. The researchers suspect direct binding to the selenium centre. Translated: the enzyme is still there, but it works more slowly, and the conversion of T4 into active T3 could suffer.
The pattern also shows up in the whole organism
In chronically mercury-exposed amphibian larvae, the thyroid was structurally damaged, and deiodinase-2 expression and glutathione peroxidase were suppressed. This adds the level of a living organism to the cellular picture, but, like all animal data, remains a hint and not proof for humans.
Chen and colleagues investigated, in human kidney cells, how mercury attacks glutathione peroxidase 4. Methylmercury bound directly to the enzyme's selenol group and inhibited it; adding selenium partly restored the activity and reduced the cell damage. For you this is a molecular hint at how closely mercury and selenium compete at selenoenzymes. What was studied is the lipid-repair isoform GPx4 in an embryonic kidney cell line, not the thyroid itself. Extending this to the thyrocyte is plausible, but it has not been measured.
Chen et al., Metallomics. 2023. DOI: 10.1093/mtomcs/mfad014Pantaleão and colleagues gave rats the mercury compound thimerosal and measured thyroid hormones and deiodinase activity. The highest dose lowered deiodinase activity in several tissues without changing the amount of enzyme. For you this means: in the animal model, a mercury compound can slow down exactly the enzymes that convert T4 into active T3. With one limitation: the substance was injected at a high dose, and of all things the deiodinase in the liver, the main site of peripheral conversion, remained unchanged. Extending this to everyday exposure therefore stays open.
Pantaleão et al., Endocr Connect. 2017. DOI: 10.1530/EC-17-0220Shi and colleagues exposed toad larvae chronically to various mercury concentrations. High doses damaged the thyroid, lowered deiodinase-2 and thyroid hormone receptor expression, and suppressed glutathione peroxidase. For you this rounds out the picture: mercury hits the thyroid via the same selenium-dependent pathways in a whole organism too, not just in cell culture.
Shi et al., Ecotoxicol Environ Saf. 2018. DOI: 10.1016/j.ecoenv.2018.08.058A heavy-metal burden could hit the thyroid through a functional selenium deficiency, that is, even when your selenium blood level looks perfectly normal. The selenium is there, but if mercury binds it, it is not available to the enzymes. Important: this functional deficiency is mechanistically plausible and has been shown in cells and animal models, but it has not been directly demonstrated in humans with Hashimoto's. It remains a well-grounded hypothesis, not a finding.
How the generic mercury–selenium mechanics work in detail, that is, the affinity for sulfur and selenium groups across all organs, is the subject of the heavy-metals overview page. Oxidative protection via glutathione is at the same time the interface with detoxification, more on that in the article on glutathione and heavy metals.
Two questions that are constantly confused
This is where a common fallacy lies. Two completely different things are often thrown into one pot, and exactly this blending produces either panic or sweeping dismissal. Kept cleanly apart, they are two questions with two different answers.
Toxic burden
Could mercury, by inhibiting the selenoenzymes, disrupt hormone activation and oxidative protection? This is the functional and metabolic level. It is not about autoimmunity but about whether the machine runs more slowly. This level is mechanistically well grounded.
Autoimmune trigger
Could mercury, acting as an adjuvant or hapten, immunologically promote an autoimmune reaction against thyroid tissue? This is the trigger level, the actual Hashimoto's question. Here the data are thinnest and most contradictory.
This distinction is the real map. A heavy metal could theoretically burden the function of your thyroid without ever triggering an autoimmune reaction. And conversely, Hashimoto's is an autoimmune disease whose initiation is a separate, immunological process. Anyone who equates "mercury disrupts enzymes" with "mercury causes Hashimoto's" leaps over a decisive gap.
What the trigger level actually offers, honestly considered
For the immunological trigger hypothesis there is an explanatory model, but only weak evidence. The idea: metal ions could activate T cells and, via signalling molecules, kick off systemic inflammation. This is the hapten and adjuvant hypothesis. It comes mostly from small, uncontrolled case series in the orbit of the MELISA test, and it is methodologically weak.
Stejskal and colleagues postulated that metal ions could activate T cells and trigger systemic inflammation via cytokines, and described health improvements after removal of intolerable dental materials. The work provides the immunological explanatory model for the trigger level, but remains hypothesis: small sample size, no control group, proximity to the test provider. For you this means taking this model seriously as a question, not as an answer.
Stejskal et al., Neuro Endocrinol Lett. 2006. PMID: 17261999 (no DOI)Why your TSH can be normal while you do not feel that way
This is one of the most common and most frustrating findings in Hashimoto's: the values are okay, you are not. The key lies in the difference between the central control and what actually arrives in your cells.
TSH is the control hormone from the pituitary gland. It says how loudly the thyroid should "call out." When enough T4 is circulating in the blood, TSH is satisfied and sits in the normal range. So much for the central level.
But T4 is only the storage form. Only the deiodinases convert it into the active T3 within the cells. If this peripheral conversion is slowed, for example because the selenium-dependent deiodinases are not running smoothly, too little active T3 may arrive where it is meant to act, while TSH and T4 still look unremarkable.
This could explain why some people, despite "good values," still feel exhausted, cold-sensitive and foggy-headed. The control is right, the local execution perhaps not. Important: this is an explanatory model, not a diagnosis that may be made across the board.
Kim and colleagues analysed a Korean environmental-health survey and linked mercury, cadmium and lead to thyroid hormones and calculated deiodinase activity. Urinary mercury was associated with lower total T3 and with reduced calculated deiodinase activity. Cadmium showed the opposite direction in the same work, that is, higher T3 and higher calculated deiodinase activity. For you this means: at the population level there are hints that mercury could slow the T4-to-T3 conversion, consistent with the deiodinase mechanism. It is an observation, not proof, and it cannot be generalised to all heavy metals.
Kim et al., Sci Total Environ. 2021. DOI: 10.1016/j.scitotenv.2020.144227The precise laboratory methodology, that is, which values to measure how and how to interpret them, does not belong in this article. Here it is only about why a normal TSH need not fully explain how you feel.
Levothyroxine is a prescription-only thyroid hormone and the basic care in Hashimoto's. The dose is delicate in both directions: too little leaves the symptoms in place, too much can over time favour heart rhythm disturbances such as atrial fibrillation and put a strain on bone density. How you take it matters too, since calcium, iron, magnesium, acid blockers and coffee can reduce absorption. Please never question or stop your levothyroxine therapy on your own, every adjustment belongs in medical hands.
The heavy-metal question is a complementary lead, not a substitute for your endocrinological care. And independently of this topic: newly appearing thyroid nodules, rapid growth, hoarseness or difficulty swallowing should be assessed medically without delay.
Selenium in Hashimoto's: why it can help, and why on its own it often is not enough
If any micronutrient has a solid evidence base in Hashimoto's, it is selenium. It is the best-supported lever of this whole topic, and at the same time the bridge to the heavy-metal question. Both hang on the same element.
Huwiler and colleagues evaluated 35 randomised trials of selenium in Hashimoto's. Selenium could lower TPO antibodies, though with very large scatter between the studies (I² = 90 percent), and TSH in people without hormone replacement, with a small effect there. Free and total T4 and T3 as well as Tg antibodies did not change significantly. Adverse effects were no more frequent than under placebo. The authors rate the certainty of the overall evidence as moderate. For you this means: selenium can measurably lower TPO antibodies, and it is the best-studied lever in Hashimoto's.
Huwiler et al., Thyroid. 2024. DOI: 10.1089/thy.2023.0556The Cochrane review by van Zuuren and colleagues summarised four controlled trials. Selenium lowered TPO antibodies in several studies, but the clinical relevance remained unclear and the evidence was overall incomplete. For you this means: while selenium does lower antibody levels, whether it reliably makes you feel better is not yet proven. Honest framing rather than a promise of cure.
van Zuuren et al., Cochrane Database Syst Rev. 2013. DOI: 10.1002/14651858.CD010223.pub2Kong and colleagues evaluated seven controlled trials. After six months there was a significant reduction in TPO and Tg antibodies; after three months there was still no clear effect. For you this means: selenium can act on the antibodies only over months, not weeks, so patience is part of it.
Kong et al., Medicine (Baltimore). 2023. DOI: 10.1097/MD.0000000000033791The findings are consistent across many studies: selenium can lower TPO antibodies. Another large meta-analysis confirms this, but points out that the effect on other values is inconsistent.
Zuo and colleagues evaluated 17 controlled trials with 1,911 participants in total. Selenium could lower TPO antibodies. TSH and Tg antibodies did not change significantly. One other finding from the same work stands out: free T3 was significantly lower under selenium, and free T4 tended to be lower as well. With existing or looming hypothyroidism that is not a neutral side finding but a reason to stay attentive. For you this means: selenium is not a switch that simply resets the thyroid picture, and it belongs under medical monitoring.
Zuo et al., Ann Palliat Med. 2021. DOI: 10.21037/apm-21-449Here the circle closes. Selenium is the cofactor of exactly those enzymes that mercury could block. If a heavy metal binds the selenium away, a pure selenium supplement could partly run into the void as long as the burden is not taken into account. So it could be not only about "too little selenium" but about "selenium that does not arrive." What is established is that selenium can lower TPO antibodies and that mercury binds selenium. That, in the Hashimoto's patient, one cancels out the other remains a plausible but unproven hypothesis.
What the human data really show, and what they do not
Now the most honest part. At the mechanistic level the data are concrete. At the level of proof in humans they are thin and contradictory. Anyone who cites only one side leaves out the other half of the studies. Let us look at both camps.
Gallagher and Meliker analysed the US health survey NHANES and examined the association between blood mercury and thyroid autoantibodies in about 2,000 women. Women with the highest mercury had roughly double the odds for thyroglobulin antibodies, while no association showed up for TPO antibodies. The threshold for the highest quintile was 1.81 micrograms per litre of blood mercury, that is, within a range a normal diet can reach. For you this means: there is a statistical signal between mercury and one thyroid antibody, but no proof of cause and only for one of the two antibodies.
Gallagher & Meliker, Environ Int. 2012. DOI: 10.1016/j.envint.2011.11.014Set against this is a whole series of null findings. Two studies found no association with thyroid antibodies despite high or oral mercury exposure respectively.
Barregard and colleagues compared mercury-exposed chloralkali workers with controls. Despite clearly elevated mercury levels, there was no significant difference in autoantibodies; the authors consider a sustained autoimmune reaction at these exposure levels to be rare. For you this is a counter-finding that calls for caution: high mercury exposure did not automatically lead to thyroid antibodies here. With limitations: only men were studied, the group was small, and the authors themselves point to the low statistical power and a possible selection effect among active workers.
Barregard et al., Int Arch Occup Environ Health. 1997. DOI: 10.1007/s004200050193Rachmawati and colleagues investigated oral metal exposure, metal allergy and autoimmune markers. Oral mercury, gold or palladium exposure was not associated with autoimmune phenomena; metal-allergic individuals even had thyroid antibodies less often. For you this means, against the blanket equation of amalgam equals autoimmune: in this study there was no association of amalgam mercury with thyroid antibodies.
Rachmawati et al., Autoimmunity. 2015. DOI: 10.3109/08916934.2015.1033688The honest core
There is no proof that mercury causes Hashimoto's. One positive signal for only a single antibody in one population study, null findings in two others. The direct link between mercury and the classic TPO antibodies is not established in humans.
The most plausible explanation for the contradictions is individual susceptibility: genetics, selenium supply, the rest of the toxin burden. The person at the next table with a similar number of fillings may have no symptoms because their biology buffers the mercury better. That is biology, not imagination, but it remains an explanatory hypothesis.
In standard endocrinological care the question of environmental toxins has so far played only a small role, and it usually stops at "cause unknown." In some holistic accounts, in turn, mercury is set as the cause although the data do not support that. Both perspectives have their reasons. This page tries to hold a middle ground: mechanistically grounded, honestly delimited, with a clear separation between what is established and what is hypothesis. Whether I succeed is for you to judge as you read.
When the heavy-metal question is worth asking in Hashimoto's, and when it is not
Not every Hashimoto's has a toxin story, and "go get detoxed" is no responsible piece of advice. But it would be equally wrong to dismiss the question across the board. There are pointers where the thought is genuinely worth pursuing, and there are situations where it tends to mislead.
Pointers where the question can make sense
- A relevant mercury history: many or long-worn amalgam fillings, a removal without a protective protocol, or occupational contact with amalgam, for example in dentistry.
- Treatment resistance despite well-controlled TSH: the values are right, the levothyroxine fits, and yet your wellbeing remains clearly impaired over a long time.
- Persistent exhaustion and brain fog that cannot be explained by the thyroid settings alone.
- Further unexplained multisystem complaints that coexist and cannot be assigned to any single organ picture.
- Regular consumption of large predatory fish such as tuna or swordfish over years, an often-overlooked methylmercury source.
When the question tends to mislead
- A freshly diagnosed Hashimoto's that responds well to treatment: here solid endocrinological care comes first.
- No exposure indications whatsoever and a symptom picture that is well explained by the thyroid and known factors.
- The expectation that a test or a course of chelation will dissolve the Hashimoto's: this expectation is not supported by the data.
Whether and how one should sensibly measure at all when there is a well-founded suspicion is a separate question. A simple blood value mainly reflects recent uptake and can underestimate a burden stored in tissue. There are so-called mobilisation tests using a chelating agent. Important for context: toxicological societies and the human biomonitoring commission judge these tests critically, because no recognised reference ranges exist for provoked excretion values. The substances used, such as DMPS, are prescription-only and not free of risk: allergic and, in rare cases, severe skin reactions are possible, essential trace elements such as zinc, copper and selenium are excreted along with the metals, and particular caution applies with impaired kidney function, because both mercury and the chelating agents affect the kidney. What such a test can and cannot achieve, I set out in the article on the DMPS challenge test, and which investigative route is suited when, in the post measuring heavy metals in blood or urine.
For a Hashimoto's that does not settle despite a cleanly controlled TSH, the question of a mercury history belongs in the conversation, in my view. Not as a promise of cure, but as one of several leads you can check before discarding it. Conventional medicine does the most important thing right here, it secures the hormone supply. What integrative medicine can add is the question of possible contributing factors in the background. The two do not exclude each other.
"Amalgam out, then the Hashimoto's is gone": why it does not work that way
This is the most common forum myth on this topic. It sounds logical and is nonetheless too short-sighted. The honest answer has three parts.
Shutting off the source makes sense
If amalgam really is a relevant source, stopping the supply can make sense. One thing matters here: the drilling out itself releases the most mercury in the short term, so it belongs under protective measures and in experienced hands. And intact, symptom-free fillings are not removed prophylactically under current assessments. That decision always belongs in the conversation with your dentist. How a removal can proceed as safely as possible is the subject of the post removing amalgam and chelating correctly.
The stored burden remains
Mercury already deposited does not disappear within a few weeks just because the filling is gone. For inorganic mercury, residence times of months to years are described depending on the tissue. That is half-life mathematics, not a failure of detoxification. Source gone does not mean burden gone.
An autoimmune reaction once set in motion can keep running
Once the immune reaction against the thyroid is under way, it can develop a momentum of its own. Even if a trigger had originally been involved, its removal does not yet mean reversal. That is clinical observation and a physiological consideration, not a rule established by studies. This is why expectation management matters more here than any promise.
Procházková and colleagues followed 35 metal-allergic autoimmune patients after an amalgam replacement. Some of the participants subsequently reported an improvement, most clearly in multiple sclerosis, not primarily in the thyroid. Because there was no control group, the group was very small and expectation plays a part, no effect can be derived from this. I name the work so that you know it, not as an argument.
Procházková et al., Neuro Endocrinol Lett. 2004. PMID: 15349088 (no DOI)To this day there is no randomised or prospective human study showing that heavy-metal chelation improves the course of Hashimoto's. This gap must be named openly. The general question of how mercury can even be chelated and with what expectations is dealt with in the article on mercury poisoning and chelation. Gentle, food-based approaches you will find in the post on natural heavy-metal elimination. How dangerous amalgam actually is and what the EU ban means is the subject of the article amalgam fillings and mercury exposure.
Evidence overview: established, plausible, open
So that you keep the overview, here are the key statements of this page with their respective evidence status, without sugar-coating.
| Statement | Evidence status | Limitation |
|---|---|---|
| Key thyroid enzymes are selenoenzymes | Strongly established | Mechanistic reviews, established textbook knowledge |
| Mercury binds and inhibits these selenium enzymes | Molecularly established | In vitro and animal model, not measured in the Hashimoto's patient |
| Selenium can lower TPO antibodies | Meta-analyses of RCTs | Clinical relevance of the antibody reduction uncertain per Cochrane |
| Functional selenium deficiency at normal blood level | Mechanistically plausible | Not directly demonstrated in humans with Hashimoto's, hypothesis |
| Mercury could slow the T4-to-T3 conversion | Animal plus observation | Population signal and animal data, no proof of causation; for cadmium the same work found the opposite direction |
| Mercury linked to thyroid antibodies | Contradictory | Signal for TgAb only in one study, two null findings |
| Mercury as an autoimmune trigger (hapten/adjuvant) | Weak, hypothesis | Small, uncontrolled case series, proximity to conflicts of interest |
| Chelation improves the course of Hashimoto's | Not established | No randomised or prospective human study available |
The thyroid is a biologically understandable target of mercury. But that does not become a diagnosis, it becomes a question you can check.
Frequently asked questions
Can heavy metals trigger Hashimoto's?
Can amalgam trigger Hashimoto's?
Why is my TSH normal even though I have symptoms?
Does selenium help with Hashimoto's?
What does Hashimoto's despite taking selenium mean?
Is it true that Hashimoto's disappears after amalgam removal?
Which heavy metals could harm the thyroid?
Should I stop my levothyroxine therapy if I chelate?
What does glutathione have to do with the thyroid?
Could my constant exhaustion come from heavy metals rather than the thyroid?
Read on in the heavy-metal cluster
This article is the thyroid deep dive of a larger topic. These posts connect directly to the points touched on here.
Heavy Metals Overview
Sources, mechanics, diagnostics in the big picture
PillarAmalgam Fillings
How dangerous the mercury really is
DMPS Challenge Test
Measuring heavy metals correctly, whether and when
Glutathione
The body's own detoxifier and cell protector
Chelating Mercury
Recognising symptoms and reducing the burden
Fatigue
When heavy metals slow the mitochondria
Sources
Tier markers: Clinical = meta-analysis, RCT or case series in humans · Human = population or observation · In vivo = animal model · In vitro = cell culture · Narrative mechanistic review = review article without its own data collection. The mechanistic plausibility is largely preclinical; the direct human evidence for causation is thin and contradictory.
- Huwiler VV, Maissen-Abgottspon S, Stanga Z et al. Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Thyroid. 2024;34(3):295-313. DOI: 10.1089/thy.2023.0556 [Meta-analysis, clinical, k=35]
- van Zuuren EJ, Albusta AY, Fedorowicz Z, Carter B, Pijl H. Selenium supplementation for Hashimoto's thyroiditis. Cochrane Database Syst Rev. 2013;(6):CD010223. DOI: 10.1002/14651858.CD010223.pub2 [Review, Cochrane, clinical, k=4, n=463]
- Kong XQ, Qiu GY, Yang ZB, Tan ZX, Quan XQ. Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(20):e33791. DOI: 10.1097/MD.0000000000033791 [Meta-analysis of controlled trials, clinical, k=7, n=342]
- Zuo Y, Li Y, Gu X, Lei Z. The correlation between selenium levels and autoimmune thyroid disease: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(4):4398-4408. DOI: 10.21037/apm-21-449 [Meta-analysis of controlled trials, clinical, k=17, n=1911]
- Gallagher CM, Meliker JR. Mercury and thyroid autoantibodies in U.S. women, NHANES 2007-2008. Environ Int. 2012;40:39-43. DOI: 10.1016/j.envint.2011.11.014 [Cross-sectional study, human, n=2047]
- Kim MJ, Kim S, Choi S et al. Association of exposure to polycyclic aromatic hydrocarbons and heavy metals with thyroid hormones in general adult population and potential mechanisms. Sci Total Environ. 2021;762:144227. DOI: 10.1016/j.scitotenv.2020.144227 [Cross-sectional study, human, n=1254]
- Barregard L, Enestrom S, Ljunghusen O, Wieslander J, Hultman P. A study of autoantibodies and circulating immune complexes in mercury-exposed chloralkali workers. Int Arch Occup Environ Health. 1997;70(2):101-6. DOI: 10.1007/s004200050193 [Controlled cross-sectional, human, n=82]
- Rachmawati D, Muris J, Scheper RJ et al. Continuing the quest for autoimmunity due to oral metal exposure. Autoimmunity. 2015;48(7):494-501. DOI: 10.3109/08916934.2015.1033688 [Case-control study, human, n=78]
- Chen J, Ma M, Wang R et al. Roles of glutathione peroxidase 4 on the mercury-triggered ferroptosis in renal cells: implications for the antagonism between selenium and mercury. Metallomics. 2023;15(3):mfad014. DOI: 10.1093/mtomcs/mfad014 [In vitro, human cells]
- Pantaleão TU, Ferreira ACF, Santos MCS et al. Effect of thimerosal on thyroid hormones metabolism in rats. Endocr Connect. 2017;6(8):741-747. DOI: 10.1530/EC-17-0220 [In vivo, rat]
- Shi Q, Sun N, Kou H, Wang H, Zhao H. Chronic effects of mercury on Bufo gargarizans larvae: Thyroid disruption, liver damage, oxidative stress and lipid metabolism disorder. Ecotoxicol Environ Saf. 2018;164:500-509. DOI: 10.1016/j.ecoenv.2018.08.058 [In vivo, amphibian larva]
- Schweizer U, Chiu J, Köhrle J. Peroxides and peroxide-degrading enzymes in the thyroid. Antioxid Redox Signal. 2008;10(9):1577-92. DOI: 10.1089/ars.2008.2054 [Narrative mechanistic review]
- Köhrle J, Gärtner R. Selenium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):815-27. DOI: 10.1016/j.beem.2009.08.002 [Narrative mechanistic review]
- Procházková J, Sterzl I, Kucerova H, Bartova J, Stejskal VDM. The beneficial effect of amalgam replacement on health in patients with autoimmunity. Neuro Endocrinol Lett. 2004;25(3):211-8. PMID: 15349088 (no DOI) [Uncontrolled case series, clinical, n=35, methodologically weak]
- Stejskal V, Hudecek R, Stejskal J, Sterzl I. Diagnosis and treatment of metal-induced side-effects. Neuro Endocrinol Lett. 2006;27(Suppl 1):7-16. PMID: 17261999 (no DOI) [Review, narrative with case series, human, methodologically weak]